ArticleBioMed research international2014
The antiacetylcholinesterase and antileishmanial activities of Canarium patentinervium Miq.
Article in BioMed research international, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 40 citations in OpenAlex.
- Syringic Acid in Canarium odontophyllum for Diabetes and Obesity - A Review.Cell biochemistry and biophysics · 2025Review
- Repurposing Acetylcholinesterase Inhibitors for Leishmaniasis: Donepezil Hydrochloride and Related Compounds Against the American Tegumentary Form.Antibiotics (Basel, Switzerland) · 2025Article
- Compound Annotation by UHPLC-MS/MS, Quantification of Phenolic Compounds and Antimicrobial Activity of Monofloral Avocado Honey.Plants (Basel, Switzerland) · 2025Article
- Natural Compounds and Health Benefits ofMolecules (Basel, Switzerland) · 2025Review
- Anti-Inflammatory and Antioxidant Effects of (6International journal of molecular sciences · 2025Article
- Antiplasmodial and Antileishmanial Activities of a New Limonoid and Other Constituents from the Stem Bark ofMolecules (Basel, Switzerland) · 2023Article
- Antileishmanial and Antiplasmodial Activities of Secondary Metabolites from the Root ofMolecules (Basel, Switzerland) · 2023Article
- Evaluation of Catechin Synergistic and Antibacterial Efficacy on Biofilm Formation andAntibiotics (Basel, Switzerland) · 2022Article
- Chemical and Bioinformatics Analyses of the Anti-Leishmanial and Anti-Oxidant Activities of Hemp Essential Oil.Biomolecules · 2021Article
- Review
- In vitro cholinesterase inhibitory action ofIn silico pharmacology · 2021Article
- Quinolizidine-Derived Lucanthone and Amitriptyline Analogues Endowed with Potent Antileishmanial Activity.Pharmaceuticals (Basel, Switzerland) · 2020Article
- Neuroprotective effects of vomifoliol, isolated from3 Biotech · 2020Article
- Antibacterial activities of the extracts, fractions and isolated compounds from Canarium patentinervium Miq. against bacterial clinical isolates.BMC complementary medicine and therapies · 2020Article
- Article
- Gastroprotective efficacy and safety evaluation of scoparone derivatives on experimentally induced gastric lesions in rodents.Nutrients · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In continuation of our natural and medicinal research programme on tropical rainforest plants, a bioassay guided fractionation of ethanolic extract of leaves of Canarium patentinervium Miq. (Burseraceae Kunth.) led to the isolation of scopoletin (1), scoparone (2), (+)-catechin (3), vomifoliol (4), lioxin (5), and syringic acid (6). All the compounds exhibited antiacetylcholinesterase activity with syringic acid, a phenolic acid exhibiting good AChE inhibition (IC50 29.53 ± 0.19 μ g/mL). All compounds displayed moderate antileishmanial activity with scopoletin having the highest antileishmanial activity (IC50 163.30 ± 0.32 μ g/mL). Given the aforementioned evidence, it is tempting to speculate that Canarium patentinervium Miq. represents an exciting scaffold from which to develop leads for treatment of neurodegenerative and parasitic diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.